PLA-Inhibitors (stoPLA): New class of NSAIDs for oral and transdermal pain treatment
Phospholipase A2 (PLA2) designates a large and diverse
group of enzymes that cleave phospholipids at the sn-2- position. This metabolic step is instrumental in a variety of pathogenic processes causing pain, fever and inflammation. Presently glucocortidoids are used for inhibition of PLA2. Unfortunately, glucocortidoids have serious side effects which limit their use as medication for pain treatment. stoPLA is a new class of heteroaryl-substituted acetone derivatives for the effective inhibition of PLA2, especially of cytosolic PLA2. These compounds effectively interact with the synthesis of prostaglandins and leukotrienes and reduce inflammatory processes. The new heteroarylsubstituted acetone derivatives have also an excellent solubility profile and are stable against metabolic inactivation through ketogroup reduction.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
A blueprint for mapping melting ice sheets
Researchers in the Stanford Radio Glaciology lab use radio waves to understand rapidly changing ice sheets and their contributions to global sea-level rise. This technique has revealed groundwater beneath Greenland,…
Water hyacinth plant pots – utilization of an invasive species
Together with Fiber Engineering GmbH, the DITF presents a process for the production of biodegradable plant pots. The products are cost effective and competitive. At the same time, the production…
Current research on the new 6G mobile communications standard
Nursing care robots, autonomous driving, digital twins: all of these high-tech applications will play an essential role for the new 6G mobile communications standard. The first commercial 6G networks are…